On July 9th, Sandoz, a division of Novartis (NVS), announced the long-awaited US retail launch of SYMJEPI in both adult and pediatric doses. SYMJEPI is single-dose, pre-filled syringe drug/device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis that was developed by Adamis Pharmaceuticals (ADMP). Prior to July 9th, Sandoz had only launched the 0.3 mg dose of SYMJEPI in the institutional setting which is approximately 15%-20% of the US epinephrine market. Now, Sandoz will rollout SYMJEPI and SYMJEPI Jr. into the larger retail market